Eric J Suba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2420011/publications.pdf

Version: 2024-02-01

1040056 888059 34 309 9 17 citations h-index g-index papers 35 35 35 214 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Systems Analysis of Real-World Obstacles to Successful Cervical Cancer Prevention in Developing Countries. American Journal of Public Health, 2006, 96, 480-487.	2.7	52
2	De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam. Cancer, 2001, 91, 928-939.	4.1	51
3	Lessons learned from successful Papanicolaou cytology cervical cancer prevention in the socialist republic of Vietnam. Diagnostic Cytopathology, 2012, 40, 355-366.	1.0	21
4	Cervical cancer prevention for all the world's women: Genuine promise resides in skilled quality management rather than novel screening approaches. Diagnostic Cytopathology, 2007, 35, 187-191.	1.0	18
5	Patient Identification Error Among Prostate Needle Core Biopsy Specimens—Are We Ready for a DNA Time-Out?. Journal of Urology, 2007, 178, 1245-1248.	0.4	17
6	Papanicolaou Screening in Developing Countries. American Journal of Clinical Pathology, 2004, 121, 315-320.	0.7	16
7	Association between war and cervical cancer among Vietnamese women. International Journal of Cancer, 2004, 110, 775-777.	5.1	16
8	Cost-Effectiveness of Cervical-Cancer Screening in Developing Countries. New England Journal of Medicine, 2006, 354, 1535-1536.	27.0	12
9	HPV Screening for Cervical Cancer in Rural India. New England Journal of Medicine, 2009, 361, 304-306.	27.0	11
10	Papanicolaou Screening in Developing Countries: An Idea Whose Time Has Come. American Journal of Clinical Pathology, 2004, 121, 315-320.	0.7	10
11	Cost-Effectiveness Studies on Cervical Cancer. Acta Cytologica, 2001, 45, 509-514.	1.3	8
12	Crossing the quality chasm: a requirement for successful cervical cancer prevention in developing countries. Clinics in Laboratory Medicine, 2004, 24, 945-963.	1.4	8
13	Coming to terms with Vietnam: The Viet/American cervical cancer prevention project. Diagnostic Cytopathology, 2005, 33, 344-351.	1.0	7
14	HPV vaccination: waiting for evidence of effectiveness. Lancet, The, 2010, 375, 639-640.	13.7	7
15	Response by Eric Suba to Sankaranarayanan et al. Indian Journal of Medical Ethics, 2014, 11, 167-75.	0.4	7
16	Re: Preventing Cervical Cancer Globally by Acting Locally: If Not Now, When?. Journal of the National Cancer Institute, 2011, 103, 611-612.	6.3	6
17	Re: Human Papillomavirus Testing in the Prevention of Cervical Cancer. Journal of the National Cancer Institute, 2011, 103, 1482-1483.	6.3	5
18	US-funded measurements of cervical cancer death rates in India: scientific and ethical concerns. Indian Journal of Medical Ethics, 2014, 11, 178-80.	0.4	4

#	Article	IF	CITATIONS
19	Direct visual inspection for cervical cancer screening. Cancer, 2004, 101, 2365-2365.	4.1	3
20	Cervical cancer mortality in India. Lancet, The, 2014, 383, 1804.	13.7	3
21	Population-based Pap screening in Cameroon. Acta Cytologica, 2003, 47, 948-9.	1.3	3
22	Human papillomavirus vaccine. New England Journal of Medicine, 2007, 357, 1155; author reply 1155-6.	27.0	3
23	Prevention of Cervical Cancer in Low-Resource Settings. JAMA - Journal of the American Medical Association, 2006, 295, 1248.	7.4	2
24	RE: Population-Level Impact of the Bivalent, Quadrivalent, and Candidate Nonavalent Human Papillomavirus Vaccines: A Comparative Model-Based Analysis. Journal of the National Cancer Institute, 2013, 105, 664-664.	6.3	2
25	Human papillomavirus screening for low and middle-income countries. Preventive Medicine, 2017, 100, 296.	3.4	2
26	Eleven questions regarding cervical cancer prevention in India. Journal of Cancer Research and Therapeutics, 2014, 10, 459.	0.9	2
27	Breast Fine-Needle Aspiration in the Socialist Republic of Vietnam: First-Year Experience in the Ho Chi Minh City Cancer Center. Breast Journal, 1996, 2, 299-303.	1.0	1
28	Self-collection of vaginal specimens for HPV testing. Lancet, The, 2012, 379, 1587-1588.	13.7	1
29	Unethical randomised controlled trial of cervical screening in India: US Freedom of Information Act disclosures. BMJ Global Health, 2017, 2, e000177.	4.7	1
30	The IARC Perspective on Cervical Cancer Screening. New England Journal of Medicine, 2022, 386, 607-608.	27.0	1
31	SUBA RESPONDS. American Journal of Public Health, 2007, 97, 201-202.	2.7	0
32	SUBA RESPONDS. American Journal of Public Health, 2007, 97, 199-200.	2.7	0
33	Response. Journal of the National Cancer Institute, 2013, 105, 1254-1255.	6.3	0
34	Correspondence regarding Castle., Human papillomavirus screening for low and middle-income countries. Preventive Medicine, 2017, 105, 357-358.	3.4	0